Business Description

Terumo Corp. is involved in the sale and manufacture of medical equipment and products. Shibasaburo Kanasato founded the company on September 17, 1921. It is headquartered in Tokyo. It has three segments: Vascular Company, Cardiac, and General Hospital Company. Cardiac and Vascular Company offers services and treatments that include cardiac and vascular surgery and interventions inside blood vessels. The Blood Management Company segment provides a mixture of manual and automated whole blood processing, apheresis collection, and pathogen reduction. The General Hospital Company segment offers closed anticancer drug injection systems and infusion, measuring devices with communication functions, diabetes management, and adhesion barrier.

Key Financials

Revenue (US$ Mn):

• US$ 5,770 Mn was Terumo Corporation’s annual revenue in 2021, a 2.07% increase from 2020 figures
• Terumo Corporation indexed a -0.51% decrease in annual revenues from 2019, amounting to US$ 5,653 Mn in 2020
• Terumo Corporation generated total revenue of US$ 5,682 Mn in 2019
• Annual revenue of US$ 5,596 Mn was indexed by Microsoft Corporation in 2018

Operating Income (US$ Mn):

• US$ 549 Mn was the operating income generated by Terumo Corporation in 2021
• Terumo Corporation’s operating income for 2020 was US$ 906 Mn, a -9.34% decrease from 2019
• From 2018’s operating incomes, Terumo Corporation registered a 0.38% increase in 2019, amounting to US$ 999 Mn
• An operating income of US$ 996 Mn was generated in 2018 by Terumo Corporation

Net Income (US$ Mn):

• Terumo Corporation’s net income for 2021 was US$ 1,563 Mn, a 119.65% increase from the 2020
• The net income generated by Terumo Corporation in 2020 was US$ 712 Mn
• At a 3.76% increase, Terumo Corporation’s net income of US$ 770 Mn was indexed in 2019
• Terumo Corporation generated a net income of US$ 742 Mn in 2018

Operating Margin %

• 10% was the operating margin generated by Terumo Corporation in 2021
• Terumo Corporation’s operating margin for 2020 was 16%, a -9.09% decrease from 2019
• From 2018’s operating margins, Terumo Corporation registered a -1.12% decrease in 2019, amounting to 18%
• An operating margin of 18% was generated in 2018 by Terumo Corporation

SWOT Analysis

Strengths:

Sustained revenue growth

The company reported strong growth in revenue in FY2020, which helps it gain investors’ confidence and improve its ability to allocate adequate funds for future growth prospects. In FY2020, Terumo reported revenue of JPY628,897 million as compared to JPY599,481 million in FY2019, representing an annual growth of 4.9%. The growth in revenue was primarily attributed to an increase in revenue from the Cardiac and Vascular business and General Hospital business. On a CAGR basis, the company recorded a growth of 4.6% from 2016 to 2020.

Get this premium content

The Premium data is Locked

Buy Now to Unlock Premium Data

Request Sample Data